Drugs Containing Valsartan Recalled
Teva Pharmaceuticals, Major Pharmaceuticals, and Solco Healthcare are voluntarily recalling their products containing valsartan because of the presence of N-nitrosodimethylamine.
On July 13, 2018, FDA announced a voluntary recall of products containing the API valsartan because the impurity N-nitrosodimethylamine (NDMA) was found in some products that contain the API, which was manufactured from a third-party supplier. Teva Pharmaceuticals Industries Ltd., Major Pharmaceuticals, and Prinston Pharmaceutical Inc. dba Solco Healthcare LLC. are recalling all lots of non-expired valsartan-containing products supplied by this third-party supplier. FDA is investigating the levels of NDMA in the products and the possible effect on patients. Not all products containing valsartan are being recalled, as not all companies use the same API supplier.
According to FDA, NDMA is classified as a probable human carcinogen. The presence of NDMA “was unexpected and is thought to be related to changes in the way the active substance was manufactured.” The API supplier has stopped the distribution of its valsartan, and the affected companies are working with FDA to reduce or eliminate the impurity from future products.
“We have carefully assessed the valsartan-containing medications sold in the United States, and we’ve found that the valsartan sold by these specific companies does not meet our safety standards. This is why we’ve asked these companies to take immediate action to protect patients,” said Janet Woodcock, M.D., director of the FDA’s Center for Drug Evaluation and Research, in a press release.
Source: FDA
Trump Directs FDA, EPA to Reduce Regulatory Barriers to Domestic Pharma Manufacturing
May 7th 2025The White House is instructing FDA to increase fees for and inspections of foreign drug manufacturing plants and reduce the time required to approve such sites that will be newly constructed in the US.
New Cancer Research and Treatment Center in Development in London
May 1st 2025Aviva Capital Partners and developer Socius are investing £1 billion in a 12-acre site to be located at the London Cancer Hub next to The Institute of Cancer Research, London and The Royal Marsden NHS Foundation Trust’s Sutton site.
Regeneron Treatment for Multiple Myeloma Gets Conditional Marketing Approval from EC
April 29th 2025The indication is specific to patients who have received at least three prior therapies, including a proteasome inhibitor, immunomodulatory agent, and anti-CD38 monoclonal antibody, and have demonstrated disease progression on the last therapy.
